deltatrials
Completed PHASE1/PHASE2 NCT00078559

Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults

The Use of Campath-1H, Tacrolimus, and Sirolimus Followed by Sirolimus Withdrawal in Renal Transplant Patients

Sponsor: Immune Tolerance Network (ITN)

Conditions Kidney Disease Kidney Transplantation
Interventions Acetaminophen Acyclovir Alemtuzumab Clotrimazole Diphenhydramine Kidney transplant Methylprednisolone (or equivalent) Nystatin Pentamidine Sirolimus Tacrolimus Trimethoprim (TMP)/Sulfa (Bactrim, Septra) Valgancyclovir
Updated 10 times since 2017 Last updated: May 29, 2018 Started: Nov 30, 2003 Primary completion: Feb 28, 2010 Completion: Feb 28, 2010

A PHASE1/PHASE2 clinical study on Kidney Disease and Kidney Transplantation, this trial is completed. The trial is conducted by Immune Tolerance Network (ITN) and has accumulated 10 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

10 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE1_PHASE2

  5. Dec 2021 — Dec 2022 [monthly]

    Completed PHASE1_PHASE2

▶ Show 5 earlier versions

  1. Jan 2021 — Dec 2021 [monthly]

    Completed PHASE1_PHASE2

  2. Jul 2018 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

  3. Jun 2018 — Jul 2018 [monthly]

    Completed PHASE1_PHASE2

  4. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

  5. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1_PHASE2

    First recorded

Nov 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Immune Tolerance Network (ITN)
  • University of Wisconsin, Madison
Data source: University of Wisconsin, Madison

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Madison, United States